North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
| Image |  |
|---|---|
| Description | scientific article published on 10 May 2017 |
| Author/s |
author: Aminah Jatoi Thomas C. Smyrk Michelle R. Mahoney Robert R McWilliams Matthew P Goetz |
| Publication date | May 10, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |